Neurophet-NTU Singapore, recognized for outstanding joint research
- Neurophet accelerates global expansion for research and partnership in AI-driven brain image analysis SEOUL, South Korea, Sept. 9, 2024 /PRNewswire/ -- Neurophet, an artificial intelligence (AI) solution company for brain disease, announced that Neurophet and NTU (Nanyang Technological University) Singapore have been recognized in the Asian Society Against Dementia (ASAD) conference...
Lunit Joins Roche’s Digital Pathology Open Environment to Advance Cancer Biomarker Testing
Lunit's AI-powered biomarker, Lunit SCOPE PD-L1 TPS, integrates into Roche's navify® Digital Pathology platform to enhance precision medicine and improve cancer biomarker testing SEOUL, South Korea, Sept. 9, 2024 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, today announced its collaboration with Roche...
GenAssist Ltd Announced the First DMD Patient Dosed with its Base Editing Drug
SUZHOU, China, Sept. 9, 2024 /PRNewswire/ -- On September 06, 2024, GenAssist Ltd (GenAssist), announced the first DMD patient dosed with its base editing drug, GEN6050X injection, in an investigator-initiated trial (IIT). "This is the first-in-human trial for DMD gene editing therapy. It marks that DMD treatment has entered the gene editing era", said Chelsie He, CEO of GenAssist,...
Frost & Sullivan grants the Global Targeted Molecular Fluorescent Tracer R&D Leadership Award to Nanjing Nuoyuan Medical Devices Co., Ltd.
SHANGHAI, Sept. 9, 2024 /PRNewswire/ -- Frost & Sullivan is pleased to announce that the 18th Growth Innovation Leadership (GIL) Summit and the 3rd New Investment Event (NIE 2024), was held in Shanghai from August 27 to 30, 2024, co-hosted by LeadLeo. Based on research and analysis of the global targeted molecular fluorescent tracer market, as well as studies...
Frost & Sullivan grants the Global Biologics CDMO Technology Leadership Award to BiBo Pharma
SHANGHAI, Sept. 9, 2024 /PRNewswire/ -- Frost & Sullivan is pleased to announce that the 18th Growth Innovation Leadership (GIL) Summit and the 3rd New Investment Event (NIE 2024), was held in Shanghai from August 27 to 30, 2024, co-hosted by LeadLeo. Based on research and analysis of the global CDMO market, as well as studies and evaluations of...
Sirsram Medical announces NMPA approval for DAXXIFY®
Marking the introduction of the world's first and only peptide-powered botulinum toxin product to Mainland China HONG KONG, Sept. 9, 2024 /PRNewswire/ -- Sisram Medical (1696.HK), a global leading innovator and provider of holistic medical aesthetic solutions announced today that the National Medical Products Administration has accepted the Biologics License Application ("BLA") for the Company's botulinum toxin, DAXXIFY® (Chinese trademark:...
Intelligent Technology Empowers the Future of Rehabilitation: Siyi Intelligence (Syrebo) Shines at WRRC 2024
i-CREATe & WRRC 2024 SHANGHAI, Sept. 9, 2024 /PRNewswire/ -- Siyi Intelligence (Syrebo) played a prominent role at the International Convention on Rehabilitation Engineering and Assistive Technology (i-CREATe 2024) & the World Rehabilitation Robot Convention 2024 (WRRC 2024), held in Shanghai from August 23rd to 26th, 2024. This event was co-hosted by the Coalition on Rehabilitation Engineering and Assistive...
MGI Launches New Nanopore Sequencing Products with Advanced CycloneSEQ Technology
SHENZHEN, China, Sept. 9, 2024 /PRNewswire/ -- MGI Tech Co., Ltd. ("MGI"), a company committed to building core tools and technologies that drive innovation in life science, today announced the global rights to commercialize and distribute the new sequencing products CycloneSEQ-WT02* and CycloneSEQ-WY01*. With potential across different areas of genomics, CycloneSEQ™ technology...
Ping An Selected for Hang Seng Corporate Sustainability Index. Series for 14th Consecutive Year
HONG KONG and SHANGHAI, Sept. 9, 2024 /PRNewswire/ -- Ping An Insurance (Group) Company of China, Ltd. (hereafter "Ping An", the "Company" or the "Group", HKEX: 2318 / 82318; SSE: 601318) has been included as a constituent member in the Hang Seng Corporate Sustainability Index Series for 2024-2025, effective immediately. Hang Seng Indexes Company recognizes Ping An's outstanding performance in...
Formosa Pharmaceuticals Makes First Shipment of APP13007 (Clobetasol Propionate Ophthalmic Suspension, 0.05%) to the United States for Commercialization
TAIPEI, Sept. 9, 2024 /PRNewswire/ -- Formosa Pharmaceuticals, Inc. (hereinafter referred to as "Formosa Pharma," 6838.TW) announced the successful first shipment to the United States of its new ophthalmic drug, Clobetasol Propionate Ophthalmic Suspension, 0.05% (APP13007), manufactured by Bora Pharmaceuticals Ophthalmic (hereinafter referred to as "Bora," 6472.TW). Formosa Pharma's U.S. partner, Eyenovia,...
